"Leiomyoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
Descriptor ID |
D007889
|
MeSH Number(s) |
C04.557.450.590.450
|
Concept/Terms |
Leiomyoma- Leiomyoma
- Leiomyomas
- Fibroid Tumor
- Fibroid Tumors
- Tumor, Fibroid
- Tumors, Fibroid
- Fibromyoma
- Fibromyomas
- Fibroid
- Fibroids
Fibroid Uterus- Fibroid Uterus
- Uterus, Fibroid
- Fibroma, Uterine
- Fibromas, Uterine
- Uterine Fibroma
- Uterine Fibromas
- Fibroids, Uterine
- Fibroid, Uterine
- Uterine Fibroid
- Uterine Fibroids
- Leiomyoma, Uterine
|
Below are MeSH descriptors whose meaning is more general than "Leiomyoma".
Below are MeSH descriptors whose meaning is more specific than "Leiomyoma".
This graph shows the total number of publications written about "Leiomyoma" by people in this website by year, and whether "Leiomyoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2003 | 2 | 0 | 2 |
2004 | 3 | 0 | 3 |
2005 | 2 | 1 | 3 |
2006 | 6 | 0 | 6 |
2007 | 1 | 0 | 1 |
2008 | 3 | 0 | 3 |
2009 | 3 | 1 | 4 |
2010 | 2 | 0 | 2 |
2011 | 6 | 0 | 6 |
2012 | 2 | 1 | 3 |
2013 | 7 | 0 | 7 |
2014 | 7 | 1 | 8 |
2015 | 7 | 0 | 7 |
2016 | 11 | 2 | 13 |
2017 | 10 | 3 | 13 |
2018 | 14 | 1 | 15 |
2019 | 4 | 0 | 4 |
2020 | 16 | 2 | 18 |
2021 | 5 | 0 | 5 |
2022 | 13 | 0 | 13 |
2023 | 21 | 0 | 21 |
2024 | 13 | 0 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leiomyoma" by people in Profiles.
-
A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. Pain Manag. 2024 Sep; 14(9):469-476.
-
Regulatory roles of NAMPT and NAD+ metabolism in uterine leiomyoma progression: Implications for ECM accumulation, stemness, and microenvironment. Redox Biol. 2024 Dec; 78:103411.
-
Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert Opin Ther Targets. 2024 Aug; 28(8):669-687.
-
Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
-
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
-
Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women. Am J Obstet Gynecol. 2024 Sep; 231(3):324.e1-324.e12.
-
Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities. Am J Obstet Gynecol. 2024 Sep; 231(3):321.e1-321.e11.
-
Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
-
Empowering Strategies for Lifestyle Interventions, Diet Modifications, and Environmental Practices for Uterine Fibroid Prevention; Unveiling the LIFE UP Awareness. Nutrients. 2024 Mar 12; 16(6).
-
Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper. Gynecol Obstet Invest. 2024; 89(2):73-86.